Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chemotherapy and cardiotoxicity]

C Brestescher1, P Pautier, D Farge

  • 1Service de Médecine Interne et Pathologie Vasculaire, Hôpital Saint-Louis, Paris.

Annales De Cardiologie Et D'Angeiologie
|October 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

British journal of cancer·2026
Same author

Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.

Gynecologic oncology·2024
Same author

Targeting the immune microenvironment in ovarian cancer therapy-mission impossible?

ESMO open·2024
Same author

Systemic sclerosis, silica exposure and cellular therapies: The sand in the gears?

La Revue de medecine interne·2024
Same author

French protocol for the diagnosis and management of hematopoietic stem cell transplantation in autoimmune diseases.

La Revue de medecine interne·2024
Same author

Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: Where do we stand? Volume II.

Frontiers in immunology·2022
Same journal

[Study of Sleep Apnea Syndrome in Patients with Chronic Heart Failure in the Cardiology Department at Yalgado Ouédraogo teaching hospital in 2024 and 2025].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Impact of knowledge and practices of hygieno-dietetical measures in hypertensive people at the Abidjan cardiology institute].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Correlation between carotid atheroma and DAS28 gamma GT score in rheumatoid arthritis in an African black population].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Dobutamine stress echocardiography: Appropriateness of indications and protocol compliance. A single-centre report].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Post-COVID postural orthostatic tachycardia syndrome: Documentation of a hyperadrenergic phenotype by comprehensive autonomic testing].

Annales de cardiologie et d'angeiologie·2026
Same journal

Urban-rural disparities in hypertension prevalence, screening, and control in South Kivu Province, eastern Democratic Republic of the Congo.

Annales de cardiologie et d'angeiologie·2026
See all related articles

Anthracyclines like doxorubicin can cause chronic heart damage during chemotherapy, dose-dependently. Early risk assessment and monitoring are crucial for managing chemotherapy-induced cardiotoxicity.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Context:

  • Chemotherapy involves various anticancer drugs with potential cardiac side effects.
  • Anthracyclines, particularly doxorubicin, are known for causing myocardial toxicity.
  • Cardiotoxicity can be acute or chronic, dose-dependent, and influenced by risk factors.

Purpose:

  • To review the cardiotoxicity associated with common anticancer drugs.
  • To highlight the mechanisms, risk factors, and management strategies for chemotherapy-induced cardiotoxicity.
  • To discuss the cardiac adverse effects of anthracyclines, 5-fluorouracil, cyclophosphamide, and interferons.

Summary:

  • Anthracyclines (e.g., doxorubicin) cause dose-dependent myocardial toxicity, necessitating cumulative dose limits (550 mg/m2) and monitoring (ultrasonography, ejection fraction).

Related Experiment Videos

  • Treatment for anthracycline-induced heart failure involves digitalis alkaloids and ACE inhibitors.
  • Other agents like 5-fluorouracil (coronary spasm), high-dose cyclophosphamide (myocarditis), and interferon (heart failure, arrhythmias) also pose cardiac risks.

    • Impact:

    • Emphasizes the importance of pre-chemotherapy risk factor analysis and regular cardiac monitoring.
    • Informs clinical practice regarding the management and treatment of chemotherapy-induced heart failure.
    • Underscores the need for awareness of diverse drug-induced cardiac toxicities in oncology.